Plamotamab  (Synonyms: XmAb-13676)

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo^[1][2].

Plamotamab 在体外诱导人 PBMC 内源性 B 细胞的杀伤和内源性 CD8⁺ T 细胞的激活，EC₅₀ 值为 0.113 nM^[2]。
Plamotamab 在体外诱导 T 细胞介导的对 Raji 肿瘤细胞的杀伤，EC₅₀ 值为 0.144 nM^[2]。
Plamotamab 结合 CD3δ/ε、CD3⁺ T 细胞、CD4⁺ T 细胞、CD8⁺ T 细胞、B 细胞、Raji 细胞，EC₅₀ 分别为 2.1 nM、11.78 nM、10.12 nM、200.3 nM 和 134.8 nM^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Plamotamab (0.17 mg/kg；腹腔注射) 在含有 Raji 异种移植物的人 PBMC 移植小鼠模型中引起肿瘤生长抑制^[2]。
Plamotamab (0.3 mg/kg；腹腔注射) 导致食蟹猴中细胞因子释放，安全性有待提高^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2138442-31-4

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.  [Content Brief]

  [2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.